GSK announced that Triumeq (generic name: dolutegravir, abacavir and lamivudine all-in-one tablet), the innovative antiretroviral (ARV) drug by its subsidiary joint venture ViiV Healthcare, was officially launched in mainland China.
Triumeq is the first Single Tablet Regimen (STR) for HIV treatment in mainland China which offers Chinese people living with HIV/AIDS the convenience of a single-pill once-a-day regimen. Triumeq, the only 3-in-1 ARV that contains dolutegravir (DTG), is highly effective and well-tolerated.
It poses a high barrier to drug resistance with few drug-drug interactions and can be administered as a single once daily tablet. Triumeq significantly reduces the pill burden on patients, enhances patient drug adherence, and significantly improves their quality of life.
Please read more here.
Comments